TNG.PA
Strong SellSinkerTransgene SA · Healthcare · France · $259M · Avg Vol: $138K/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
ABOUT TRANSGENE SA
Read
Transgene SA is a French biotechnology company specializing in the design and development of virus-based immunotherapies, including therapeutic vaccines and oncolytic viruses for cancer treatment. The company's competitive moat is anchored by its proprietary viral vector platforms, Invir.IO and myvac, which enable highly personalized cancer treatments. Transgene operates as a specialized niche player in the advanced biopharmaceutical sector, leveraging strategic partnerships to fund clinical trials.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.5M | 1.4M | 0.3M | 0.5M | -47.9% | 7.2M | 0.5M | 0.5M | -0.1% |
| EPS (EUR) | -0.12 | -0.08 | -0.14 | -0.26 | — | -0.26 | -0.14 | -0.22 | — |
| Shares | 278.3M | 278.3M | 278.3M | 273.9M | -1.6% | 278.3M | — | — | — |
| Debt | 2.4M | 1.3M | 17.0K | 0 | -91.7% | 2.1M | — | — | — |
| Equity | 37.8M | 15.6M | 15.2M | 121.7M | 47.6% | — | — | — | — |
| Op CF | -20.3M | -34.7M | -23.5M | -37.0M | — | -37.0M | — | — | — |
| Inv CF | 20.3M | 34.6M | -3.2M | -106.0M | — | — | — | — | — |
| Fin CF | -1.5M | 11.4M | 27.0M | 134.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TNG.PA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TNG.PA | Transgene SA(you) | $259M | 18 | Strong Sell |
| IPH.PA | Innate Pharma S.A. | $243M | 17 | Strong Sell |
| CLLS | Cellectis S.A. | $342M | 6 | Strong Sell |
| VALN | Valneva SE | $610M | 12 | Strong Sell |
| ALSEN.PA | Sensorion SA | $162M | 3 | Strong Sell |
| MEDCL.PA | MedinCell S.A. | $1.0B | 21 | Sell |
| ALGAE.PA | Fermentalg SA | $64M | 21 | Sell |
| 0QAV.L | Nanobiotix S.A. | $627M | 5 | Strong Sell |
| DBVT | DBV Technologies S.A. | $851M | 8 | Strong Sell |
| ALTHX.PA | THX Pharma Société Anonyme | $71M | 9 | Strong Sell |
Peer medians: ROE -33.6% · P/E 22.9x · Gross margin 72.6%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.